Purpose: Adenoid cystic carcinoma (ACC) is a heterogeneous malignancy, and no effective
systemic therapy exists for metastatic disease. We previously described two prognostic ACC …

Abstract Background B7-H3 and B7-H4 are highly expressed by many human malignancies
making them attractive immunotherapeutic targets. However, their expression patterns and …

ABSTRACT B7-H4, an immune suppressive member of the B7 family, is highly expressed in
a wide variety of human malignancies making it an attractive immunotherapeutic target …

B7-H3 is over-expressed in multiple types of solid tumors, making it an ideal target for
chimeric antigen receptor (CAR)-T therapy. Here we first report a case of multiple basal cell …

Abstract B7-H4, as a member of the costimulatory B7 family, serves a critical role in the
negative regulation of T cell-mediated antitumor immune responses. Cholangiocarcinoma …

Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate
(median 15.7 months, 13.1–17.8), with only a 23% response rate to monotherapy treatment …

Novel systemic agents and effective treatment strategies for recurrence adenoid cystic
carcinoma (ACC) of the head and neck are still worthy of further exploration. Here, we …

Abstract Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in
non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby …

New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …

Pulmonary invasive mucinous adenocarcinoma (IMA) is considered a variant of lung
adenocarcinomas based on the current World Health Organization classification of lung …